Ten-Year Retention Rate of Infliximab in Patients with Behcet's Disease-Related Uveitis

被引：40

作者：

Fabiani, Claudia ^{[1
]}

Sota, Jurgen ^{[2
,3
]}

Vitale, Antonio ^{[2
,3
]}

Emmi, Giacomo ^{[4
]}

Vannozzi, Lorenzo ^{[5
]}

Bacherini, Daniela ^{[5
]}

Lopalco, Giuseppe ^{[6
]}

Guerriero, Silvana ^{[7
]}

Venerito, Vincenzo ^{[6
]}

Orlando, Ida ^{[2
,3
]}

Franceschini, Rossella ^{[8
]}

Fusco, Fiorella ^{[8
]}

Frediani, Bruno ^{[2
,3
]}

Galeazzi, Mauro ^{[2
,3
]}

Iannone, Florenzo ^{[6
]}

Tosi, Gian Marco ^{[8
]}

Cantarini, Luca ^{[2
,3
]}

机构：

[1] Humanitas Clin & Res Ctr, Dept Ophthalmol, Via Manzoni 56, I-20089 Rozzano, MI, Italy

[2] Univ Siena, Dept Med Sci Surg & Neurosci, Res Ctr Syst Autoinflammatory Dis, Siena, Italy

[3] Univ Siena, Dept Med Sci Surg & Neurosci, Behcets Dis & Rheumatol Ophthalmol Collaborat Uve, Siena, Italy

[4] Univ Florence, Dept Expt & Clin Med, Florence, Italy

[5] Univ Florence, Dept Surg & Translat Med, Eye Clin, Florence, Italy

[6] Univ Bari, Interdisciplinary Dept Med, Rheumatol Unit, Bari, Italy

[7] Univ Bari, Dept Ophthalmol & Otolaryngol, Bari, Italy

[8] Univ Siena, Ophthalmol & Neurosurg Dept, Siena, Italy

来源：

OCULAR IMMUNOLOGY AND INFLAMMATION | 2019年 / 27卷 / 01期

关键词：

Behcet's disease; drug retention rate; infliximab; treatment; uveitis; LONG-TERM EFFICACY; REFRACTORY UVEORETINITIS; PROGNOSTIC-FACTORS; TNF-ALPHA; MULTICENTER; ADALIMUMAB; EXPERIENCE; ATTACKS;

D O I：

10.1080/09273948.2017.1391297

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Purpose: To evaluate the 10-year drug retention rate of infliximab (IFX) in Behcet's disease (BD)-related uveitis, the effect of a concomitant use of disease modifying anti-rheumatic drugs (DMARDs) on drug survival and differences according to the lines of biologic treatment. Methods: Cumulative survival rates were studied using the Kaplan-Meier plot, while the Log-rank (Mantel-Cox) test was used to compare survival curves. Results: Forty patients (70 eyes) were eligible for analysis. The drug retention rates at 12-, 24-, 60- and 120-month follow-up were 89.03%, 86.16%, 75.66% and 47.11% respectively. No differences were identified according to the use of concomitant DMARDs (p = 0.20), while a statistically significant difference was observed in relation to the different lines of IFX treatment (p = 0.014). Visual acuity improved from baseline to the last follow-up visit (p = 0.047) and a corticosteroid-sparing effect was observed (p < 0.0001). Conclusions: IFX retention rate in BD-uveitis is excellent and is not affected by concomitant DMARDs.

引用

页码：34 / 39

页数：6

共 35 条

[1] Safety and efficacy of infliximab therapy in active Behcet's uveitis: an open-label trial [J].

Al-Rayes, H. ;

Al-Swailem, R. ;

Al-Balawi, M. ;

Al-Dohayan, N. ;

Al-Zaidi, S. ;

Tariq, M. .

RHEUMATOLOGY INTERNATIONAL, 2008, 29 (01) :53-57

[2]

[Anonymous], 1990, Lancet, V335, P1078

[3] Clinical Experience with Adalimumab in the Treatment of Ocular Behcet Disease [J].

Bawazeer, Ahmed ;

Raffa, Lina H. ;

Nizamuddin .

OCULAR IMMUNOLOGY AND INFLAMMATION, 2010, 18 (03) :226-232

[4] Safety profile of biologic agents for Behcet's disease in a multicenter observational cohort study [J].

Cantarini, Luca ;

Talarico, Rosaria ;

Generali, Elena ;

Emmi, Giacomo ;

Lopalco, Giuseppe ;

Costa, Luisa ;

Silvestri, Elena ;

Caso, Francesco ;

Franceschini, Rossella ;

Cimaz, Rolando ;

Iannone, Florenzo ;

Galeazzi, Mauro ;

Selmi, Carlo .

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2017, 20 (01) :103-108

[5] Validation of the revised International Criteria for Behcet's Disease (ICBD) in Iran [J].

Davatchi, Fereydoun ;

Abdollahi, Bahar Sadeghi ;

Chams-Davatchi, Cheyda ;

Shahram, Farhad ;

Nadji, Abdolhadi ;

Shams, Hormoz ;

Faezi, Tahereh ;

Akhlaghi, Massoomeh ;

Ashofteh, Farimah ;

Mataji, Maryam ;

Moradi, Kamran ;

Mohtasham, Negin .

CLINICAL RHEUMATOLOGY, 2015, 34 (02) :315-320

[6] Behcet's syndrome pathophysiology and potential therapeutic targets [J].

Emmi, Giacomo ;

Silvestri, Elena ;

Squatrito, Danilo ;

D'Elios, Mario Milco ;

Ciucciarelli, Lucia ;

Prisco, Domenico ;

Emmi, Lorenzo .

INTERNAL AND EMERGENCY MEDICINE, 2014, 9 (03) :257-265

[7] Drug Retention Rates and Treatment Discontinuation among Anti-TNF-α Agents in Psoriatic Arthritis and Ankylosing Spondylitis in Clinical Practice [J].

Fabbroni, Marta ;

Cantarini, Luca ;

Caso, Francesco ;

Costa, Luisa ;

Pagano, Veronica Anna ;

Frediani, Bruno ;

Manganelli, Stefania ;

Galeazzi, Mauro .

MEDIATORS OF INFLAMMATION, 2014, 2014

[8] Quality of life impairment in Beh‡et's disease and relationship with disease activity: a prospective study [J].

Fabiani, Claudia ;

Vitale, Antonio ;

Orlando, Ida ;

Sota, Jurgen ;

Capozzoli, Marco ;

Franceschini, Rossella ;

Galeazzi, Mauro ;

Tosi, Gian Marco ;

Frediani, Bruno ;

Cantarini, Luca .

INTERNAL AND EMERGENCY MEDICINE, 2017, 12 (07) :947-955

[9] Efficacy and safety of adalimumab in Beh‡et's disease-related uveitis: a multicenter retrospective observational study [J].

Fabiani, Claudia ;

Vitale, Antonio ;

Emmi, Giacomo ;

Vannozzi, Lorenzo ;

Lopalco, Giuseppe ;

Guerriero, Silvana ;

Orlando, Ida ;

Franceschini, Rossella ;

Bacherini, Daniela ;

Cimino, Luca ;

Soriano, Alessandra ;

Frediani, Bruno ;

Galeazzi, Mauro ;

Iannone, Florenzo ;

Tosi, Gian Marco ;

Salvarani, Carlo ;

Cantarini, Luca .

CLINICAL RHEUMATOLOGY, 2017, 36 (01) :183-189

[10] Ocular Involvement in Systemic Autoimmune Diseases [J].

Generali, Elena ;

Cantarini, Luca ;

Selmi, Carlo .

CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2015, 49 (03) :263-270

← 1 2 3 4 →